DelveInsight’s ’Biliary Atresia (BA)– Epidemiology Forecast?2030’ report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Biliary Atresia (BA) Disease Understanding
Biliary Atresia (BA) Overview

Biliary Atresia is a neonatal liver disease characterized by progressive obstruction and fibrosis of the extrahepatic biliary tree along with fibrosis and inflammation of the liver parenchyma. The etiology and pathogenesis of BA remain unknown. Recent studies are examining potential pathogenetic mechanisms of BA, including genetic susceptibility, the involvement of the immune system, and environmental insults such as viruses and toxins. It is possible that there is not a single etiological agent but rather a large group of injurious insults that might result in a final common pathway of extrahepatic bile duct obstruction and liver fibrosis.
The symptoms of biliary atresia usually appear by the age of 2–6 weeks. They include a yellowish coloration of the skin and whites of the eyes (jaundice), abnormally pale stools, and dark urine. Infants may also have swollen (distended) stomach and/or abnormal enlargement of the liver (hepatomegaly). The pathway from clinical suspicion to establishing the diagnosis of biliary atresia in a child with jaundice is a daunting task?however, investigations available help point the correct diagnosis in a reasonable time frame.Imaging by sonography has identified several parameters which can be of help in the diagnostic workup. Comparison of sonography with imaging by nuclear medicine can bring out significant differences and also avoid inappropriate imaging. The battery of biochemical tests, available currently, enable a better understanding of the line-up of investigations in a given child with neonatal cholestasis. Untreated, biliary atresia remains a fatal condition of the newborn. Most present within 4–6 weeks of conjugated jaundice and acholic stools, and although still a challenging diagnosis to make, therein lies the opportunity of changing the course of this otherwise inexorable disease.
Biliary Atresia (BA) Epidemiology
The Biliary Atresia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Biliary Atresia epidemiology segmented as the Total Incident Cases of Biliary Atresia, Type-specific Cases of Biliary Atresia, and Gender-specific Cases of Biliary Atresia. The report includes the Incident scenario of Biliary Atresia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country Wise- Biliary Atresia (BA) Epidemiology
The epidemiology segment also provides the Biliary Atresia (BA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total Incident population of Biliary Atresia in the 7MM countries was estimated to be 613 in 2017.
As per the estimates, the United States has the highest Incident population of Biliary Atresia.

  • Among the EU5 countries, UK had the highest Incident population of Biliary Atresia with 45 cases, followed by France which had Incident population of 42 in 2017. On the other hand, Spain had the lowest Incident population of 27 cases in 2017.


Scope of the Report

  • Biliary Atresia (BA) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • Biliary Atresia (BA) Epidemiology Report and Model provide an overview of the risk factors and global trends of Biliary Atresia (BA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Biliary Atresia (BA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Biliary Atresia
  • The report provides the segmentation of the Biliary Atresia (BA) epidemiology by Incident Cases of Biliary Atresia (BA) in 7MM
  • The report provides the segmentation of the Biliary Atresia (BA) epidemiology by Type -specific and Gender-specific Incident Cases of Biliary Atresia (BA) in 7MM




Report Highlights

  • 11-Year Forecast of Biliary Atresia (BA) epidemiology
  • 7MM Coverage
  • Total Incident Cases of Biliary Atresia (BA)
  • Incident Cases according to segmentation: Type-specific cases of Biliary Atresia (BA), Gender-specific cases of Biliary Atresia (BA)


KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Biliary Atresia (BA)?
  • What are the key findings pertaining to the Biliary Atresia (BA) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
  • What would be the total number of patients of Biliary Atresia (BA) across the 7MM during the forecast period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
  • What is the disease risk, burden and unmet needs of the Biliary Atresia?
  • What are the currently available treatments of Biliary Atresia?




Reasons To Buy
The Biliary Atresia (BA) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Biliary Atresia (BA) market
  • Quantify patient populations in the global Biliary Atresia (BA) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Biliary Atresia (BA) therapeutics in each of the markets covered
  • Understand the magnitude of Biliary Atresia (BA) population by its Incidence cases
  • Understand the magnitude of Biliary Atresia (BA) population by its Etiology-specific cases
  • The Biliary Atresia (BA) epidemiology report and model were written and develoBA by Masters and Ph.D. level epidemiologists
  • The Biliary Atresia (BA) Epidemiology Model develop by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017–2030
The Biliary Atresia Research Consortium in the USA, the European Biliary Atresia Registry in Europe, and the Japanese Biliary Atresia Registry (JBAR) have been formed to help with data collection and provide a platform for large research studies.